A dverse cardiovascular events, including cardiac death and stent thrombosis, are markedly increased among those with versus without chronic kidney disease (CKD) after percutaneous coronary intervention (PCI).
High Platelet Reactivity in CKD independent correlate of adverse events after PCI. [6] [7] [8] [9] Common risk factors for both CKD and HPR suggest a shared pathophysiologic substrate and putative mechanistic links between renal dysfunction, platelet aggregation, and increased thrombosis. This hypothesis is indirectly supported by clinical observations demonstrating that the impact of clopidogrel in reducing ischemic events is attenuated in the setting of CKD. 10, 11 Although CKD modulates platelet function, existing studies evaluating associations between CKD and HPR have been limited by modest sample sizes, lack of adequate multivariable adjustment, and limited follow-up. [12] [13] [14] [15] [16] [17] Moreover, and perhaps more clinically relevant, whether HPR exerts a similar or differential impact on both ischemic and bleeding events among those with and without CKD after PCI is unknown. Accordingly, we sought to examine the cross-sectional and longitudinal associations among CKD, HPR, and clinical events in a contemporary cohort of patients undergoing PCI with DES.
Methods

Study Design and Patients
As previously described in detail, Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents (ADAPT-DES) was a multicenter, prospective registry designed to evaluate the relationship between platelet reactivity and clinical events in patients treated with aspirin and clopidogrel after successful DES implantation. Consecutive patients at each participating center who were treated with ≥1 DES approved by the US Food and Drug Administration or CE Mark and were adequately loaded with aspirin and clopidogrel were eligible for enrollment. Patients with major periprocedural complications or with planned bypass surgery after PCI were excluded; otherwise there were no restrictions to enrollment. For purposes of the present analysis, we only included those patients with valid platelet function tests and nonmissing values for serum creatinine, yielding a final study population of 8410 consecutive patients (from 8582 total enrolled).
The study was approved by the Institutional Review Board at every participating center, and all eligible patients signed written informed consent.
Platelet Function Testing
Platelet reactivity was assessed after successful PCI and adequate clopidogrel loading using the VerifyNow Aspirin, P2Y 12 , and IIb/IIIa assays (Accumetrics, San Diego, CA). Aspirin was given as either (1) a nonenteric-coated oral dose of ≥300 mg at least 6 hours before PCI or (2) a chewed dose of 324 mg or intravenous dose of ≥250 mg at least 30 minutes before PCI. Clopidogrel was given as either (1) a dose of 600 mg at least 6 hours before VerifyNow testing, (2) a dose of 300 mg at least 12 hours before VerifyNow testing, or (3) a dose of ≥75 mg for at least 5 days before VerifyNow testing. If eptifibatide or tirofiban were used during PCI, a 24-hour washout period was required before VerifyNow testing. No patients receiving abciximab were enrolled. HPR to adenosine diphosphate was defined as VerifyNow P2Y 12 >208.
18
End Points
Clinical follow-up occurred at 30 days, 1 year, and 2 years. Stent thrombosis was classified according to the Academic Research Consortium definition. 19 Myocardial infarction (MI) was defined by the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) criteria. 2 Clinically relevant bleeding was defined as a thrombolysis in myocardial infarction major or minor bleed, a Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) bleed, an ACUITY major bleed, or any postdischarge bleeding event requiring medical attention. An independent clinical events committee masked to VerifyNow results adjudicated all death, MI, and stent thrombosis events using original source documents. Major adverse cardiac events were defined as cardiac death, MI, or ischemia-driven target lesion revascularization.
Statistical Analysis
Creatinine clearance (CrCl) was calculated in all patients using the Cockcroft-Gault formula. 20 CKD was defined as CrCl <60 mL/min. Further categorization of patients in sensitivity analyses were performed by stratifying by level of CrCl into the following groups: <30 mL/min, 30 to 60 mL/min, and ≥60 mL/min. Pre-procedural serum creatinine was used for CrCl calculations. Coronary calcification was qualitatively defined as the presence of readily apparent radioopacities within the vascular wall at the site of the stenosis. 21 The prevalence of HPR was calculated in each category and compared across groups using the χ 2 test. Multivariable logistic regression was used to examine the association between level of CrCl and HPR after adjusting for the following confounders: age, male sex, race, body mass index, current smoker, history of diabetes mellitus, insulin treatment, hypertension, hyperlipidemia, peripheral arterial disease, congestive heart failure, previous MI, previous coronary artery bypass surgery, ST-segment-elevation MI, non-ST-segment-elevation MI, hyperlipidemic agents, warfarin, proton-pump inhibitor, prehospital admission aspirin use, prehospital admission thienopyridine use, bivalirudin, hemoglobin, white blood cell count, platelet count, use of DES alone, number of stents, number of vessels treated, and total lesion length. Covariates were selected according to baseline differences between CKD groups or previously established links with HPR even in the absence of differences (ie, lesion length). 22 Fully fitted models including all covariates were generated with CrCl ≥60 mL/min serving as the referent category for the CKD exposure.
Crude event rates at 2 years for both ischemic and bleeding events were estimated using the Kaplan-Meier method among those with and without CKD and after substratifying all participants by both CKD and HPR. Because of the small number of patients with CrCl <30 mL/min, CKD was categorized as a binary variable (present or absent with CrCl <60 mL/min) for survival analyses. Event rates were compared across groups using the log-rank test. Hazard ratios for adverse events associated with HPR were calculated using Cox
WHAT IS KNOWN
• Chronic kidney disease is associated with an increased risk for adverse events in patients undergoing percutaneous coronary intervention.
• High platelet reactivity (HPR) is also an independent correlate of thrombotic events after percutaneous coronary intervention.
• Risk factors for both chronic kidney disease and HPR demonstrate substantial overlap.
WHAT THE STUDY ADDS
• HPR increases in a dose-dependent fashion with worsening renal function.
• The higher prevalence of HPR in patients with chronic kidney disease is primarily related to comorbid risk factors that increase as renal function worsens.
• The impact of HPR on both ischemic and bleeding complications after percutaneous coronary intervention is similar irrespective of chronic kidney disease status.
proportional hazards regression within each CKD stratum. Hazard ratios for these models were stratified by propensity score quintile for HPR as previously described 9 without further covariate adjustment. Formal interaction testing was performed between the main effects of CKD and HPR on both ischemic and bleeding outcomes. Multiple sensitivity analyses were performed to evaluate the consistency of our overall findings. These included repeating all analyses using a different threshold to define HPR (P2Y 12 reactivity units ≥230), defining CKD using the CKD Epidemiology Collaboration (CKD-EPI) formula, 23 excluding patients with postprocedural rise in serum creatinine exceeding 25% of the baseline value and examining associations using an exploratory end point of net adverse clinical events that comprised bleeding or major adverse cardiac events.
Results
Baseline clinical, laboratory, and procedural characteristics stratified by severity of CKD are shown in Tables 1 and 2 . Worsening renal function was associated with older age, female sex, and non-white race. The prevalence of most comorbidities, including hypertension, diabetes mellitus, peripheral arterial disease, and previous coronary artery bypass surgery, were all higher among those with versus without CKD. Baseline use of proton-pump inhibitors and warfarin was also significantly greater among those with CKD.
Patients with CKD were more likely to have multivessel or left main (stenosis >50%) coronary artery disease. There were no differences in the number of lesions treated, lesion length, or stents implanted per patient across groups. Coronary lesions in patients with CKD were more frequently calcified while other high-risk features, such as treatment of bifurcation or chronic total occlusion lesions, did not vary by renal function. The most commonly implanted stents were second-generation everolimus-eluting stents with no difference across groups. Similarly, the frequency of first generation paclitaxel-and sirolimus-eluting stents did not vary across renal function groups. In contrast, rapid-release zotarolimus-eluting stents were used more commonly among those with versus without CKD.
The crude prevalence and adjusted odds ratios for HPR by CrCl group are shown in Figure 1 and Table 3 . The prevalence of HPR increased in a graded fashion with worsening renal function with ≈2-fold higher odds for HPR among those with a CrCl <30 mL/min versus CrCl ≥60 mL/min. However, after multivariable adjustment, these associations were attenuated with no significant associations detected between HPR and CKD.
Average follow-up was slightly longer in the CKD versus non-CKD participants (682.5±135.2 days versus 663.8±161.2 days; P<0.001). Compared with their non-CKD counterparts, patients with CKD experienced higher rates of adverse ischemic and bleeding events at 2 years ( Figure 2 ). In contrast, ischemic event rates were higher among those with versus without HPR, but bleeding rates were lower among those with HPR irrespective of renal function. As shown in Figure 3A , 2-year major adverse cardiac event rates among those without CKD or HPR, HPR alone, CKD alone, and both CKD and HPR were 9.0%, 11.2%, 13.3% and 17.5%, respectively (P<0.001). Similar patterns of higher risk were observed for cardiac death, MI, or definite/probable stent thrombosis ( Figure 3B ), and definite/probable stent thrombosis ( Figure 3C ). As shown in Figure 3D , bleeding rates across these same 4 groups were 7.8%, 7.1%, 15.4%, and 12.4%, respectively (P<0.001). Adjusted hazard ratios for ischemic and bleeding events associated with HPR and stratified by presence or absence of CKD are shown in Table 4 . These hazard ratios were similar in magnitude and direction across CKD groups with no evidence of interaction between CKD and HPR on any end point (all P int >0.05).
Results of our sensitivity analyses are presented in the Appendix I in the Data Supplement. Associations between HPR and adverse events were consistent with our overall findings after excluding patients with postprocedural increase in serum creatinine exceeding 25% of the baseline value (n=550; Table I in the Data Supplement). Use of an alternative threshold to define HPR (P2Y 12 reactivity units ≥230) yielded similar results as the 208 cutoff as shown in Tables II and III in the Data Supplement. Results remained unchanged after classifying CKD using the CKD-EPI formula (Tables IV and V in the  Data Supplement) . In all analyses, associations between HPR and net adverse clinical events remained nonsignificant irrespective of CKD status. Finally, results were unchanged after excluding patients with CKD reporting a history of dialysis (n=81, data not shown).
Discussion
The primary findings from this post hoc analysis of the ADAPT-DES registry are that HPR is significantly more common among patients with versus without CKD, and the prevalence of HPR increases in a graded fashion as renal function worsens. After multivariable adjustment, however, these associations were attenuated suggesting that confounding risk factors, rather than renal dysfunction itself, account for HPR in the setting of CKD. Nonetheless, the presence of HPR was a significant independent risk factor for thrombotic events irrespective of underlying renal function, with the highest risk among those with both CKD and HPR and lower risk among patients without CKD or HPR. Moreover, concordant reductions in bleeding risk were also observed among those with HPR with or without concomitant CKD. With >1000 patients with CKD prospectively enrolled in the ADAPT-DES registry, our results provide novel and clinically relevant insights on the complex interrelationships between CKD, platelet reactivity, and cardiovascular risk after PCI with DES. Although several earlier reports have examined the association between renal impairment and platelet reactivity after PCI, results thus far have been inconsistent as previous studies were limited by modest sample sizes, inclusion of select cohorts, or lack of adequate multivariable adjustment. 14, 16, 17, 24 In stable diabetic patients, for example, Angiolillo et al 24 previously demonstrated an independent association between CKD and HPR. Similarly, in a separate cohort involving 316 post-PCI patients with and without DM, Gremmel et al 16 also demonstrated a significant association between CKD and HPR using different assays. Our findings documenting a higher prevalence of HPR among those with versus without CKD, therefore, are largely confirmatory of these previous reports. In contrast to these observations, however, Morel et al 14 detected no such association in an acute coronary syndromes cohort. Analogously, results from Mangiacapra et al 17 also revealed no increase in platelet reactivity among post-PCI patients with moderate-to-severe CKD compared with those with preserved renal function. In contrast to these reports, the ADAPT-DES registry enrolled a large all-comers cohort undergoing PCI with minimal exclusion criteria and collected data on multiple risk factors that might confound the association between CKD and HPR. As a result, we were able to demonstrate that HPR prevalence is substantially higher among those with CKD and increases as renal function worsens. Attenuation of these associations after multivariable adjustment, however, suggests that renal dysfunction does not independently influence HPR but rather is a marker of comorbid conditions that augment platelet reactivity in the setting of CKD. Diabetes mellitus, older age, and congestive heart failure, for example, are consistent correlates of HPR 25 and also increase in prevalence as renal function worsens. The higher unadjusted prevalence of HPR in CKD compared with non-CKD patients that we observed, therefore, is a reflection of the differences in underlying baseline characteristics between these populations.
Although HPR is a well-established correlate of adverse events after PCI, 6, 7, 9 the relevance of platelet function testing on longitudinal outcomes in the setting of CKD remains less clear. In contrast to previous reports our large sample size, coupled with a 2-year follow-up, allowed us to demonstrate substantial heterogeneity in risk for both ischemic and bleeding events based on CKD and HPR status. The presence of HPR further amplified the underlying thrombotic risk of CKD because patients with both abnormalities were at highest risk for ischemic events. In contrast, those with preserved renal function and absent HPR were at lowest risk. Analogous findings were observed for bleeding events, although HPR was independently predictive of a lower, rather than higher, risk for bleeding complications across levels of renal function. The step-wise gradient in risk for adverse events we observed across CKD and HPR strata is a novel finding and highlights the prognostic implications of both metrics in estimating longterm risk after PCI with DES. It is important to note, however, that the impact of HPR may be less significant in patients with non-PCI. For example, Gurbel et al 26 previously found that associations between HPR and adverse events were completely attenuated after multivariable adjustment suggesting that HPR is a marker, rather than an independent contributor, to ischemic risk in the context of medically managed acute coronary syndromes. Whether HPR confers similar risk in patients with CKD not undergoing PCI warrants further evaluation.
Our results also demonstrate that thrombotic risk remains substantial in patients with CKD, irrespective of HPR status. Indeed, ischemic event rates among patients with CKD and normal platelet reactivity were numerically higher than in those with HPR but preserved renal function. There are several possible explanations for the increased thrombotic risk of patients with CKD, independent from HPR. First, CKD augments nonpurinergic pathways of platelet aggregation, rendering such patients at greater risk for thrombosis, despite normal P2Y 12 reactivity unit levels. Previous work by Angiolillo et al and others 16, 24, 27 also suggest a state of generalized platelet hyperactivity in the setting of CKD with or without concomitant diabetes mellitus. Second, increased levels of vascular smooth muscle cell tissue factor and serum fibrinogen in patients with CKD may lead to activation of the coagulation cascade, thereby increasing blood thrombogenicity. 28, 29 Third, atherosclerotic plaques in patients with CKD are characterized by increased amounts of necrotic core and decreased fibrous volume, potentially enhancing plaque vulnerability. 30 In aggregate, findings of excess thrombotic risk in the absence of HPR highlight the putative role of non-adenosine diphosphate-mediated pathways of platelet aggregation as additional determinants of cardiovascular risk in patients with CKD. Although it is well established that both ischemic and bleeding complications are high among patients with CKD after PCI, a novel finding from this study is that this risk is not uniform but varies substantially by the presence or absence of HPR. We found that the associations between HPR and clinical events were similar in magnitude and direction among those with and without CKD with no evidence of interaction. HPR may thus be a useful biomarker for risk stratification of patients with CKD after PCI. An untested hypothesis from our findings is whether platelet function testing may facilitate clinical decision making vis a vis choice of antiplatelet therapy in highrisk CKD patients. Although recent studies have not found utility in use of platelet function testing to guide antiplatelet therapy, these studies did not specifically examine high-risk patients with renal dysfunction. 31, 32 In the present analysis, the presence of HPR identified a group of patients with CKD in whom the risk/benefit ratio for potent platelet inhibition may be more favorable than those without HPR. Because bleeding rates also increase with CKD, however, the apparent protection from bleeding with HPR among such patients may be clinically relevant. Whether such a tailored approach to antiplatelet therapy after PCI among patients with CKD may be clinically beneficial warrants prospective evaluation. Although subgroup analyses suggest that ticagrelor or prasugrel may be comparable or even more efficacious to clopidogrel in high-risk acute coronary syndromes patients with CKD, the lack of dedicated randomized comparisons in such patients renders such hypotheses speculative at present. 33, 34 Moreover, the clinical use of platelet function testing in a real-world setting remains unknown as existing studies have not shown clinical value in using such an approach in a systematic or selective manner.
An important limitation of this study is its observational design, which precludes causal inferences. Because platelet reactivity and serum creatinine was only measured at a single point in time, we are unable to comment on whether the associations between CKD and HPR are stable over time. Similarly, serum creatinine was measured at time of the index procedure alone, and CKD status may change during follow-up. We may have also underestimated the prevalence of CKD as urinary albumin was not collected. We did not collect information on atrial fibrillation, which is common in CKD and increases risk after PCI. However, we did adjust for warfarin use, which is strongly associated with atrial fibrillation 35 and atrial fibrillation is the most common reason for anticoagulation in patients with PCI. 36 Because bleeding was a composite and site reported, rather than adjudicated, end point we were unable to evaluate associations using different definitions or severity of bleeding. We enrolled limited number of patients with CrCl <30 mL/min, precluding risk estimates in this group. Platelet reactivity was only assessed using the VerifyNow assay, which is a convenient methodology but may be influenced by laboratory parameters. 37 Finally, as all patients in this study were treated with clopidogrel our results may not be generalizable to those receiving newer antiplatelet agents, such as prasugrel or ticagrelor.
In conclusion, results from this post hoc analysis of the ADAPT-DES registry demonstrate that the higher prevalence of HPR among those with versus without CKD is largely attributable to confounding risk factors rather than an independent effect of renal impairment. The independent impact of HPR on both ischemic and bleeding events, however, is substantial, and similar among those with and without CKD.
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